TARA
Protara Therapeutics Inc.
$7.26
+$0.82(+12.73%)
75
Overall
60
Value
90
Tech
--
Quality
Market Cap
$165.54M
Volume
1.67M
52W Range
$2.36 - $10.48
Target Price
$25.00
Company Overview
| Mkt Cap | $165.54M | Price | $7.26 |
| Volume | 1.67M | Change | +12.73% |
| P/E Ratio | -3.7 | Open | $6.47 |
| Revenue | -- | Prev Close | $6.44 |
| Net Income | $-44.6M | 52W Range | $2.36 - $10.48 |
| Div Yield | N/A | Target | $25.00 |
| Overall | 75 | Value | 60 |
| Quality | -- | Technical | 90 |
No chart data available
About Protara Therapeutics Inc.
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy for patients receiving parenteral nutrition and fluids. The company is headquartered in New York, New York.
Sector: Manufacturing
Industry: Biological Product (except Diagnostic) Manufacturing
Latest News
Protara Therapeutics Announces Promising Phase 2 Trial Results
TipRanks Auto-Generated Newsdesk•4 days ago
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | TARA | $7.26 | +12.7% | 1.67M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Protara Therapeutics Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW